4.3 Article

Exosomal lncRNA NEAT1 from cancer-associated fibroblasts facilitates endometrial cancer progression via miR-26a/b-5p-mediated STAT3/YKL-40 signaling pathway

Journal

NEOPLASIA
Volume 23, Issue 7, Pages 692-703

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.neo.2021.05.004

Keywords

EC; CAFs; exosome; NEAT1; miR-26a; b-5p-STAT3-YKL-40 axis

Categories

Funding

  1. National Natural Science Foundation of China [81960464]
  2. Guangxi Natural Science Foundation [2018GXNSFAA050146]

Ask authors/readers for more resources

The study revealed that exosomal NEAT1 from cancer-associated fibroblasts contributes to the progression of endometrial cancer (EC) via modulation of the miR-26a/b-5p-mediated STAT3/YKL-40 pathway, indicating the therapeutic potential of exosomal NEAT1 for treating EC.
Cancer-associated fibroblasts cells (CAFs) confer a rapid growth and metastasis ability of endometrial cancer (EC) via exosomesmediated cellular communication. Long non-coding RNA nuclear enriched abundant transcript 1 (lncRNA NEAT1) drives the malignant phenotypes of EC cells. However, the role of exosomal NEAT1 from CAFs in EC progression remains ambiguous, which needs to be investigated. In our study, NEAT1 and YKL-40 were up-regulated, while miR-26a/b-5p was down-regulated in EC tissues. Moreover, NEAT1 expression was increased in CAF-exosomes compared with that in NF-exosomes. In addition, the exosomal NEAT1 derived from CAFs could transfer to EC cells and promote YKL-40 expression. Further exploration showed that exosomal NEAT1 enhanced YKL-40 expression via regulating miR-26a/b-5p-STAT3 axis in EC cells. More importantly, exosomal NEAT1 accelerated in vivo tumor growth via miR-26a/b-5p-STAT3-YKL-40 axis. Taken together, our study reveals that exosomal NEAT1 from CAFs contributes to EC progression via miR-26a/b-5p-mediated STAT3/YKL-40 pathway, which indicates the therapeutic potential of exosomal NEAT1 for treating EC.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available